Please note that UPSpace will be offline from 20:00 on 9 May to 06:00 on 10 May (SAST) due to maintenance. We apologise for any inconvenience caused by this.
 

Minireview : immunotherapy and its role in cancer

dc.contributor.authorVisagie, M.H. (Michelle Helen)
dc.contributor.authorJoubert, Annie M.
dc.contributor.emailannie.joubert@up.ac.zaen_US
dc.date.accessioned2011-03-22T11:54:39Z
dc.date.available2011-03-22T11:54:39Z
dc.date.issued2010-03
dc.description.abstractImmunotherapy entails treatments that stimulate, enhance or inhibit a patient’s own im-mune system to challenge a specific disease. The immune system is capable of distinguishing between healthy and tumorigenic cells and the following treatments are aimed at those cells that become cancerous. There are three approaches employed in immunotherapy namely monoclonal antibody administration, immunotherapy making use of cytokines and vaccine-based immunotherapy. Artificially produced monoclonal antibodies are employed to target tumorigenic cells by exerting an antagonistic effect on growth factor receptors or to contrib-ute to the induction of antibody-dependent cell-mediated cytotoxicity. These actions result in the disruption of tumorigenic cells or improvement of the immune response directed against tumorigenic cells. Monoclonal antibodies blocking cytotoxic T-lymphocyte associated pro-tein 4 resulted in tumor regression. Several cytokines are responsible for the stimulation of immune responses directed against tumorigenic cells. Various cytokines also stimulate tumor necrosis factor family members for induction of apoptosis in tumorigenic cells. Vaccines en-tail an active immunotherapeutic approach in which an immune response is induced by the external administration of antigens. Three different cancer vaccines are currently in use namely vaccines preventing cancer recurrence of treated cancers, eradication of cancer cells not destroyed by previous treatment and targeting of cancer-causing viruses. However, it is clear that immunotherapy should be used in combination with other known treatments to have the optimal effect.en_US
dc.description.sponsorshipThis work was supported by grants from the Medical Re-search Council of South Africa (AG374, AK076), the Cancer Association of South Africa (AK246) and the Struwig-Germeshuysen Cancer Research trust of South Africa (AJ038, AN074).en_US
dc.identifier.citationVisagie, M & Joubert, A 2010, 'Minireview : immunotherapy and its role in cancer', Biomedical Research, vol. 21, no. 4, pp. 377-381. [http://www.jstage.jst.go.jp/browse/biomedres]en_US
dc.identifier.issn0388-6107
dc.identifier.urihttp://hdl.handle.net/2263/16095
dc.language.isoenen_US
dc.publisherBiomedical Research Pressen_US
dc.rightsBiomedical Research Pressen_US
dc.subjectImmunotherapyen_US
dc.subjectMonoclonal antibody (MAb)en_US
dc.subjectCytokinesen_US
dc.subjectVaccinesen_US
dc.titleMinireview : immunotherapy and its role in canceren_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Visagie_Minireview(2010).pdf
Size:
140.95 KB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
2.44 KB
Format:
Item-specific license agreed upon to submission
Description: